Home

mainback
mainback
Accelerating Therapy/Tracer
Development
Slide
Automatic Organ Segmentation

Retrospective 57 patient Phase I/II study comparing AIQ technology to experienced reader for evaluating heterogeneous system amyloid build up in multiple organs.

“This approach will significantly impact the ease of use and improve accuracy of image interpretation that will ultimately benefit clinical management of patients with amyloidosis.”

- Weisman et al., WMIC 2021

Click to View Full Poster
Slide
Assess Organ-Specific Toxicity: Immunotherapy Application

Retrospective study of 58 melanoma patients treated with ICI therapy evaluated in a partnership with University of Wisconsin Carbone Cancer Center.

Accurate quantification of changes in the lung could significantly predict which patients had pneumonitis prior to actual diagnosis with an AUC of 0.99.

Click to View Immunotherapy Application Note
Slide
Assess Organ-Specific Toxicity:
Theranostics Application

13 prostate cancer patients from a Phase I/II trial treated with 177 Lu-PSMA-617 and imaged pre- and post-treatment with 68Ga-PSMA11-PET.

Quantification of PSMA expression shows
1. Associations between PSMA PET SUV and response by both overall survival and PSA response
2. Associations between degree of PSMA PET SUV in PSMA-expressing non-tumor tissues and adverse events

Nauseef et al., American Society of American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU) 2022.

Click to View Full Poster
previous arrow
next arrow
Our AI-driven software technologies provide comprehensive treatment response assessments from imaging scans to improve patient outcomes.

Therapy Development

More Efficient Clinical Trials

  • Treatment Response
  • Toxicity Assessment
  • Patient Selection


Learn More…

Tracer Development

Deeper Understanding of Radiopharmaceuticals

  • Uptake Assessment
  • Concordance Analysis
  • Longitudinal Changes


Learn More…

Intended for research use only. Not intended for use in treatment of patients.

“Partnering with AIQ Solutions on their new technology has been an enjoyable and productive collaboration. We share a mutual goal of improving patient care by leveraging innovative technology.”

Dr. Elisabeth I. Heath, M.D., FACP
Professor of Oncology and Medicine
Karmanos Cancer Institute

“The AIQ software will greatly improve the interpretation of PET/CT and PET/MRI scans in patients who have had multiple exams. The analysis of these exams will be more thorough and comprehensive and should save the interpreting nuclear medicine physician or radiologist a lot of time.

The ability to determine which lesions have responded to therapy and which are resistant in patients with a large metastatic disease burden will allow great improvements in patient care and hopefully lead to improved survival in oncology patients. Software like this will surely be an important part of image interpretation in the future.”

Dr. Scott Perlman M.D., M.S.
University of Wisconsin School of Medicine and Public Health
Consultant to AIQ

Alessandra Cesano, MD, PhD
Chief Medical Officer, ESSA Pharma

Alessandra Cesano, MD, PhD is the Chief Medical Officer at ESSA Pharma since July 2019. Previously she has been the Chief Medical Officer of NanoString Inc from July 2015 until June 2019 where she focused in the development of translational and diagnostic multi-plexed assays for the characterization and measurement of mechanisms of immune response/resistance. Prior to joining NanoString, Dr. Cesano was Chief Medical Officer at Cleave Biosciences, Inc. and before then she served as Chief Medical Officer and Chief Operations Officer at Nodality, Inc., where she built and led the R and D group, while providing the overall clinical vision for the organization. Between 1998 and 2008, Dr. Cesano held various management positions at Amgen, Biogen Idec and SmithKline Beecham Pharmaceuticals, where she helped to advance various oncology drugs through late stage development and FDA approvals. Early in her professional career Dr. Cesano spent 12 years conducting research in tumor immunology, including nine years at the Wistar Institute, an NCI Basic Cancer Center connected with the University of Pennsylvania. She also holds membership in several professional and scientific societies including ASCO, ESMO, ASH, EHA, AACR and SITC. In the latter she serves as co-chair in the SITC Industry Committee, Associate Editor for the Biomarker section of JITC and is an active member of the SITC Biomarker Working Group. Over her careers she has been an author on over 140 publications. Dr. Cesano received an MD summa cum laude, a Board Certification in Oncology and a PhD in Tumor Immunology from the University of Turin.

This will close in 40 seconds

Giovanni Selvaggi, PhD
Chief Medical Officer, Xcovery

Dr. Selvaggi held global positions of increasing responsibility in clinical development at various global pharmaceutical companies prior to joining Xcovery in March 2019. Dr. Selvaggi joined the pharmaceutical industry in 2010 as Medical Director in the MAGE-A3 lung cancer vaccine program at GSK. He then played an instrumental role in the successful development and approval of ceritinib (Zykadia) in ALK-translocated NSCLC at Novartis in 2013. Most recently, Dr. Selvaggi was part of the immunotherapy team at Bristol-Myers Squibb, serving as a program lead in thoracic malignancies, with a focus on SCLC and mesothelioma, leading to the approval of nivolumab (Opdivo) in third line SCLC indication with NDA in 2018. Dr. Selvaggi received his medical degree at the University of Torino School of Medicine, in Torino, Italy, in 1992 and served as staff physician of thoracic oncology at the University Hospital in Torino, participating in several clinical trials in lung cancer and mesothelioma over a span of 16 years.

This will close in 40 seconds

Eric Horler
President and Chief Executive Officer, AIQ Solutions

Eric Horler joined AIQ Solutions as its first President and CEO in September 2018. He has led AIQ through two rounds of equity financing, team construction, product commercialization, and international expansion. Before joining the AIQ team, Eric was President and CEO of Swallow Solutions LLC, a medical device start-up with both therapeutic devices and functional beverages for dysphagia patients. Before that, Eric was General Manager, Premium Anesthesia and Respiratory Care at GE Healthcare. While at GEHC, Eric was responsible for a $220 million global business and a large team spread over three continents. He has also held a series of marketing and business development roles at Baxter Healthcare, including Director of Renal Products and Services for the Latin America region. Eric has a B.S. in Chemical Engineering from Rice University and both an MBA and Master of Engineering Management degrees from the Kellogg School of Business. He lives in Madison with his wife and two children.

This will close in 40 seconds

Information on this page is intended for research use only. Applications and/or claims listed are not currently cleared for use in treatment of patients.